Introduction
Idiopathic pulmonary arterial hypertension (IPAH) is a disorder characterized by an abnormally raised mean pulmonary arterial pressure greater than 25 mm Hg at rest or greater than 30 mm Hg during exercise.
Due to changes in pulmonary arterial pressure, an increase in the resistance to blood ß ow through arteries cells can be stimulated by a number of inß ammatory mediators, including endotoxin, interleukin-1, and tumor necrosis factor; as well as Þ broblast growth factor-2, angiotensin-2, and lipids. Plasminogen activator inhibitor-1 is secreted in active form, but subsequent conformational changes can make it inactive.
The genetic variation in 3'UTR in the gene sequence of PAI has a Hind III restriction site and appears to play an important regulatory role in eventual antigen expression.
[5] Furthermore, speciÞ c external factors may also selectively enhance the regulation of each allelic form of the gene.
[6]
The 3'UTR polymorphisms of the PAI-1 gene have been found to contribute in the regulation of its expression, which suggests a genotype-speciÞ c interaction between these polymorphisms. [7] The RFLP/HindIII polymorphism in the 3' region of the Þ brinolytic protein plasminogen activator inhibitor (PAI-1) inß uences the plasma levels of PAI-1 and is reported to be associated with the development of cardiovascular disease. [8] Polymorphisms in the PAI-1 promoter region (4G/5G) and 3'UTR were found to be associated with venous thrombosis.
[9] Hence genotyping of PAI-1 was carried out to identify if any speciÞ c genotype was associated with IPAH. Table 4 ].
Materials and Methods
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Discussion
Synthesis and expression of PAI-1 at transcriptional level are, to a large extent, stimulated by transforming growth factor β-1 (TGF β-1), released from the alpha granules of platelets after vascular injury. [13] In the present study, an association of Hd2/Hd2 genotype with IPAH was observed, supporting earlier studies. This can be explained on the basis of interaction of TGF-β and coagulants pathway that may be involved in the pathogenesis of IPAH.
An interesting observation of the study was the predominance of Hd2 allele in women that was found to be signiÞ cantly associated with the disease. Since female preponderance is reported in IPAH, [14] it is possible that this allele could be one of the predisposing risk factors in women, acting in conjuncture with other inß uencing factors such as sex hormones. Our hypothesis is supported by a previous study where signiÞ cantly increased t-PA antigen and t-PA activity in correlation with mPAP, as well as increased PAI-1 activity, was reported in women with IPAH, and this presence of gender differences in the plasmin-and thrombin-activation system in IPAH leading to an antiÞ brinolytic/prothrombotic state was suggested as a possible explanation for the female predominance in the disease.
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The odds ratio of Hd2 allele was found to be signiÞ cant when compared to HD1 allele in IPAH. Thrombosis of pulmonary vessels is a common Þ nding in IPAH, where it is found with a frequency of 30% to 60%.
[16] These thrombotic events are likely to be involved in the progression of the disease by hindering tissue repair and thus contributing to the altered vasculature/ architecture that is commonly seen in IPAH.
With respect to clinical parameters, an increase in the mean level of right ventricular systolic pressure was observed in the Hd2/Hd2 genotypic patients, strengthening the role of Hd2 allele in the etiopathogenesis of IPAH in correlation to severity and poor prognosis.
Conclusion
Our data suggests an association of Hd2/Hd2 genotype with the disease, and may be responsible for up-regulation of PAI-1 which competes with plasminogen activators and impairing the normal mechanism of plasminogen activation system. This activation may contribute signiÞ cantly to IPAH by promoting thrombosis and Þ brosis, leading to tissue remodeling of the lung.
The Hd2 allele could be a predisposing factor for female preponderance in IPAH, but this needs to be ascertained on a larger sample size.
